Tau Imaging With JNJ067
Latest Information Update: 02 Sep 2022
At a glance
- Drugs JNJ-067 (Primary) ; Pittsburgh compound B
- Indications Alzheimer's disease; Dementia; Mild cognitive impairment; Progressive supranuclear palsy
- Focus Diagnostic use
Most Recent Events
- 29 Aug 2022 Status changed from active, no longer recruiting to completed.
- 23 Mar 2020 Planned primary completion date changed from 1 Jan 2020 to 1 Jan 2021.
- 23 Mar 2020 Status changed from recruiting to active, no longer recruiting.